Tumor-Associated Peptides Binding MHC Class I
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current methods for identifying and characterizing tumor-associated antigens (TAAs) are imprecise, as they do not effectively select peptides that can bind to human MHC class I molecules and elicit a specific immune response, limiting their effectiveness in tumor immunotherapy.
Innovation Solution
Identification and development of novel amino acid sequences for tumor-associated peptides that can bind to human MHC class I molecules, allowing for the selection of specific peptides capable of eliciting a cytotoxic T cell response against tumor cells.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Measurement precision
If current methods for identifying tumor-associated antigens are used, then the process is simple and quick, but the precision and effectiveness of selecting peptides that bind to MHC class I molecules and elicit immune response is insufficient
Solution Approach 1:
The patent applies preliminary action by pre-selecting and characterizing peptides with confirmed MHC class I binding capability before using them in immunotherapy. The invention identifies and catalogs specific peptide sequences (SEQ ID NO: 1-577) that have been verified to bind to MHC class I molecules and elicit CTL responses, so that clinicians can directly use these pre-validated peptides without needing to perform complex de novo screening processes.
Solution Approach 2:
The patent applies parameter changes by focusing on specific amino acid sequence parameters and MHC binding affinity parameters to identify effective tumor-associated peptides. The invention establishes specific criteria for peptide selection including MHC binding affinity, immunogenicity, and tumor specificity, transforming the vague process of TAA identification into a quantifiable parameter-based selection system.
2Reliability
If tumor vaccines are developed using traditional antigen identification methods, then the development process is faster, but the ability to elicit effective cytotoxic T cell response is limited
Solution Approach 1:
The patent applies preliminary action by pre-identifying and characterizing 577 specific peptide sequences that have been verified to bind to MHC class I molecules and elicit cytotoxic T cell responses. This pre-characterization work is done in advance, allowing clinicians to immediately use these validated peptides for tumor vaccine development without time-consuming screening processes.
Solution Approach 2:
The patent applies copying by creating a comprehensive catalog of validated peptide sequences (SEQ ID NO: 1-577) that can be replicated and used across different clinical applications. Once a peptide is identified and validated in the patent, its sequence can be copied and used in multiple vaccine formulations and clinical trials, saving time and resources.
3Manufacturing precision
If comprehensive peptide screening is performed to ensure MHC binding and immune recognition, then the quality of tumor vaccine is improved, but the complexity and resource requirements increase
Solution Approach 1:
The patent applies preliminary action by performing comprehensive MHC binding assays, proteasome processing assays, and T cell recognition assays in advance to validate each peptide sequence. The 577 peptides listed in the patent have already undergone this rigorous quality control process, so manufacturers can use them with confidence without needing to perform the entire screening process themselves.
Solution Approach 2:
The patent applies taking out by extracting and isolating only the essential characteristics needed for effective tumor vaccine peptides: MHC class I binding capability, proteasome processing efficiency, and T cell recognition. The invention separates these critical functions from the complex whole-protein antigens, focusing on the specific peptide fragments (8-10 amino acids) that contain the essential immunogenic information.
Data Source
AI summary
The invention relates to a tumor-associated peptide with an amino acid sequence selected from the group consisting of SEQ ID NO. 1 to SEQ ID NO. 577 from the attached sequence protocol, the peptide being capable of binding to a molecule of the human major histocompatibilityg complex (MHC) class I. The invention further relates to the use of the peptides for preparation of a drug and for the treatment of tumor diseases and/or adenomatous diseases. Furthermore, a pharmaceutical composition is described comprising at least one of the peptides.